- Home
- EEA vs DXR Comparison
EEA vs DXR Comparison
Compare EEA & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EEA | DXR |
|---|---|---|
| Founded | 1986 | 1970 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 69.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EEA | DXR |
|---|---|---|
| Price | $11.00 | $12.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 9.2K | 7.4K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.27 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.45 | $6.55 |
| 52 Week High | $9.26 | $14.76 |
Technical Indicators
Market Signals| Indicator | EEA | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 38.98 |
| Support Level | $10.71 | $11.87 |
| Resistance Level | $10.97 | $12.90 |
| Average True Range (ATR) | 0.23 | 0.63 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 51.80 | 12.00 |
Price Performance
Historical ComparisonAbout EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.